Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
AssigneeLentigen Technology, Inc.
InventorsDina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims21
-32. (canceled)
A method of generating a population of RNA-engineered cells comprising introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain comprising a CD19/CD22 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD19/CD22 tandem CAR comprises the amino acid sequence comprising SEQ ID NO:
- 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, or 83, thereby generating the population of RNA-engineered cells.
A method of providing an anti-tumor immunity in a mammal comprising administering to the mammal an effective amount of an isolated T cell or an isolated natural killer (NK) cell, wherein the isolated T cell or the isolated NK cell comprises a vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain comprising a CD19/CD22 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD19/CD22 tandem CAR comprises the amino acid sequence comprising SEQ ID NO:
- 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, or 83, thereby providing the anti-tumor immunity in the mammal.
A method of treating or preventing cancer in a mammal, comprising administering to the mammal an effective amount of an isolated T cell or an isolated NK cell, wherein the isolated T cell or the isolated NK cell comprises a vector comprising a nucleic acid molecule encoding a CAR comprising an extracellular antigen binding domain comprising a CD19/CD22 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD19/CD22 tandem CAR comprises the amino acid sequence comprising SEQ ID NO:
- 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, or 83, thereby treating the cancer in the mammal to treat or prevent cancer in the mammal.
-48. (canceled)
Dependencies are inferred from the claim text.